The Defense Health Agency awarded a $1,927,373.00 Project Grant to the Fred Hutchinson Cancer Center (also doing business as the Seattle Cancer Care Alliance) to support the "DEVELOPMENT OF TARGETED THERAPIES FOR METASTATIC PROSTATE CANCERS CLASSIFIED BY SUBTYPES OF DNA REPAIR DEFICIENCY" over a period of 3 years from February 2025 to February 2028. This award falls under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the general public. The research aims to develop novel targeted therapies for metastatic prostate cancers based on their underlying DNA repair deficiencies.
Generated 3/4/25, 7:50 AM